Company:

0750 Stemline Therapeutics Inc

Contract Type:

Permanent

Join us in shaping the future of Menarini - with passion, integrity, and a deep commitment to people.

About Menarini Group

Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.

Position Title:

IT AI Product Owner

Reports to:

Head of AI Engineering

Our company is seeking an IT AI Product Owner to support the operation and continuous improvement of our AI-enabled business solutions/products, with a specific focus on Generative Engine Optimization (GEO) — the discipline of ensuring company brands, products, and scientific content are accurately represented, discoverable, and favorably surfaced across AI-driven search and answer engines (e.g., ChatGPT, Perplexity, Gemini, Copilot, and similar generative platforms). This role sits at the intersection of IT operations, and business function teams such as digital marketing/communications, and content governance, and requires someone comfortable working across technical systems, business stakeholders, and compliance requirements unique to the life sciences industry.

The ideal candidate will combine solid technical/business analysis skills with curiosity about the evolving generative AI search landscape, and will be comfortable owning a recurring monitoring cadence, translating findings into actionable recommendations, and partnering with Marketing, Medical/Regulatory, and IT teams to keep company content accurate and optimized.

What Success Looks Like

• AI solution incidents and enhancement requests are resolved efficiently, with strong stakeholder satisfaction.
• A consistent, well-documented GEO monitoring cadence is in place, surfacing issues before they become reputational or compliance risks.
• Content updates driven by GEO insights are implemented on schedule and demonstrably improve the accuracy and visibility of company assets in AI-generated answers.
• IT, Marketing, Medical, and Regulatory teams view this role as a trusted, proactive partner on AI and digital content matters.

Business Translation & Agile Backlog Management:

Translation of complex, unstructured business workflows and strategic goals into clear, actionable user stories, acceptance criteria, and system requirements that IT and engineering teams can immediately execute within an Agile/Scrum environment.

Serve as day-to-day operational support for internal AI solutions/tools (e.g., generative AI writing assistants, chatbots, internal copilots, AI-enabled analytics platforms), monitoring performance, availability, and adoption.

Triage and resolve or escalate incidents, access requests, and configuration issues related to AI platforms in partnership with IT infrastructure, vendors, and business owners.

Support governance activities including AI tool intake, risk/compliance reviews, and maintenance of an AI use-case inventory.

Coordinate user acceptance testing (UAT), release notes, and training materials for AI solution updates and rollouts.

GEO Monitoring & Analysis

Conduct regular (weekly/monthly) monitoring of how company brands, products, pipeline assets, and scientific/medical content appear across generative AI search and answer engines.

Track accuracy, completeness, sentiment, and citation sources of AI-generated responses referencing company assets; flag misinformation, outdated data, or off-label/non-compliant representations for immediate escalation.

Benchmark company visibility in AI-generated answers against competitors and industry standards; maintain a GEO scorecard/dashboard of findings and trends over time.

Stay current on GEO/AI search best practices (structured data, content authority signals, schema markup, source citation patterns, llms.txt and similar emerging standards) and evaluate their applicability to company digital assets.

Partner with IT and analytics teams to build or maintain lightweight tools, scripts, or dashboards that automate GEO monitoring where feasible.

Content Strategy & Updates

Translate GEO monitoring findings into concrete, prioritized recommendations for content updates across owned digital properties (websites, HCP/patient portals, press releases, product pages, structured data).

Partner with Marketing, Corporate Communications, Medical Affairs, and Regulatory/Legal to route recommended content changes through appropriate medical-legal-regulatory (MLR) review and approval workflows.

Support implementation of approved content updates in collaboration with web/content teams, ensuring changes are applied consistently across channels and properly tagged/structured for machine readability.

Maintain documentation of GEO findings, actions taken, and outcomes to demonstrate impact and support continuous improvement.

Cross-Functional Collaboration & Reporting

Prepare regular reports and presentations summarizing AI solution performance and GEO monitoring insights for IT leadership and business stakeholders.

Act as a liaison between IT, Marketing/Digital, Medical, and Regulatory/Compliance functions on matters involving AI tools and public-facing content accuracy.

Contribute to the development of internal standards, playbooks, and SOPs governing GEO monitoring and AI solution support.

Required Qualifications

• Bachelor’s degree in information technology, Business, Computer Science, Marketing, Communications, or a related field (or equivalent experience).
• 8-10+ years of experience as a Business Analyst, IT Analyst, Digital Analyst, or similar hybrid technical/business role in a life sciences, pharma, or biotech commercial, medical, or healthcare organization.
• Demonstrated experience supporting or administering software/SaaS platforms, including gathering requirements, coordinating testing, and managing stakeholder communication.
• Familiarity with generative AI tools and platforms (e.g., ChatGPT, Perplexity, Copilot, Gemini) and a genuine interest in how AI is changing search and content discovery.
• Conceptual understanding of comprehensive AI Tech Stack: Demonstrate conceptual understanding and practical application of RAG (Retrieval-Augmented Generation), Graph RAG, Large Language Models (LLMs), Generative Engine Optimization (GEO), AI Search Optimization (AISO), Answer Engine Optimization (AEO), NLP, Predictive Analytics, Multi-Hop Retrieval, Entity-Based SEO, Knowledge Graphs, Semantic Structures, Vector Embeddings, Prompt Engineering, Intent Analysis, Data Chunking, etc.
• Working knowledge of SEO fundamentals and emerging GEO/AEO (Answer Engine Optimization) concepts, such as structured data, schema.org markup, content authority, and citation optimization.
• Strong analytical skills with the ability to synthesize monitoring data into clear, actionable insights for non-technical stakeholders.
• Excellent written and verbal communication skills; comfortable presenting findings to cross-functional and leadership audiences.
• Experience working within a regulated industry (life sciences, pharmaceutical, biotech, or healthcare) with an understanding of MLR/promotional review processes, or strong willingness and ability to learn.

Preferred Qualifications

• Experience with content management systems (CMS), digital asset management (DAM), or web analytics platforms (e.g., Adobe Analytics, Google Analytics, Sitecore, AEM).
• Familiarity with AI/LLM monitoring or brand-visibility tools, or experience building custom tracking using APIs, Python, or low-code automation tools.
• Understanding of pharmaceutical promotional and medical communication compliance requirements (e.g., FDA OPDP guidance, PhRMA Code).
• Experience with project management or ticketing tools (e.g., Jira, ServiceNow, Azure DevOps).

NY Convenience of the Employer Statement:

This position is classified as a corporate office position. In accordance with the New York state employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Base Salary Range:

$160000-190000. Menarini Stemline offers generous compensation and benefits packages, including, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

Base Salary Range of:

$175000. Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business.

For more details on how we handle your data, please refer to our Privacy Policy.